Efficacy in KEYNOTE-045
| End point | PembrolizumabN = 270 | ChemotherapyN = 272 |
|---|---|---|
| OS, no. of events | 155 | 179 |
| Median (95 % CI), months | 10.3 (8.0-11.8) | 7.4 (6.1-8.3) |
| HR (95 % CI) | 0.73 (0.59-0.91); P = 0.0022 | |
| PFS, no. of events | 218 | 219 |
| Median (95 % CI), months | 2.1 (2.0-2.2) | 3.3 (2.3-3.5) |
| HR (95 % CI) | 0.98 (0.81-1.19); P = 0.42 | |
| ORR (95 % CI) | 21.1 % (16.4-26.5) | 11.4 % (7.9-15.8) |
| Treatment difference, % (95 % CI) | 9.6 (3.5-15.9); P = 0.0011 | |